Milrinone

Cardiac Therapy · Phosphodiesterase type-3 inhibitor

Indications

Short term IV therapy of severe CHF.

Dosage

Adults: Initial dose IV; 50 mcg/kg over 10 min, Followed by IV infusion at a rate of 0.375 - 0.75 mcg per kg/min following surgery for up to 12 hr or in CHF for 48-72 hrs. Max, 1.13 mg/kg/day.

Administration

IV: Infuse via infusion pump continuous IV infusion 20 mg per 100 mL 0.9% NS or D5W.

Adverse Effects

Ventricular tachycardia, supra ventricular arrhythmias, ectopic beats, hypotension, headache, atrial fibrillation.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Risk cannot be ruled out. Lactation: Caution advised or effect undetermined. Precautions: Avoid in severe obstructive aortic or pulmonic valvular disease, atrial fibrillation & flutter. Not recommended in acute MI. Monitor fluid electrolytes balance, renal dysfunction.

Advice to Patient

Seek help if there is increased need of urination. Contact prescriber if there is pain at infusion site, numbness or tingling of extremities, or respiratory difficulty, dizziness, light-headedness, no improvement or worsening of condition. Avoid alcohol during treatment. Change position slowly from sitting or lying to standing especially in morning. Keep all doctors and labs appointments.

Pharmacokinetics

Onset of action: IV: 5-15 min. Metabolism: Hepatic (minor), majority is not metabolized. Half-life elimination: Infants (after cardiac surgery): 3.5 ± 2 hrs. Children (after cardiac surgery): 1.86 ± 2 hrs. Adults: Heart failure: 2.3-2.4 hrs. Renal impairment prolongs half-life. Severe heart failure undergoing continuous venovenous hemofiltration: 20.1 ± 3.3 hrs. Excretion: Urine.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.